Biologic therapies—omalizumab, dupilumab, mepolizumab, tezepelumab, benralizumab—have transformed allergy and immunology care, but verifying benefits for them is a nightmare. Each drug has different site-of-care rules, specialty pharmacy requirements, and patient assistance pathways. Verification mistakes lead to canceled infusions, write-offs, and patients who can't afford their therapy.